[Carcinoembryonic antigen and immunity in breast cancer]. 1991

T P Iakimova, and I N Lozinskaia, and T B Kozyreva, and N S Pashchenko

Three groups of breast cancer patients were investigated: with a high level of CEA, with a lowered level of CEA, and those in whom CEA was undetectable either before or after therapy. The relationship of the time course of blood CEA, nonspecific body reactivity, and radiotherapeutic efficacy was established. Ineffective radiotherapy resulted in inhibition of phagocytic activity of blood neutrophils and cell stromal reactions at a tumor bed against a decrease in CEA concentration as compared to the basal levels in patients. Effective radiotherapy led to increased CEA levels, phagocytic activity was unihibited and slightly on the decrease. A considerable effect of the a CEA level on the T-system of immunity was unnoticed. In the group with the absence of blood CEA, there was an increase in the phagocytic activity of blood neutrophils and cell stromal reactions in a tumor against a background of a higher ability of lymphocytes to a spontaneous blast transformation reaction and a lesser decrease in the T-lymphocyte count that in the other groups.

UI MeSH Term Description Entries
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D010587 Phagocytosis The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (PHAGOCYTES). Phagocytoses
D011879 Radiotherapy Dosage The total amount of radiation absorbed by tissues as a result of radiotherapy. Dosage, Radiotherapy,Dosages, Radiotherapy,Radiotherapy Dosages
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012397 Rosette Formation The in vitro formation of clusters consisting of a cell (usually a lymphocyte) surrounded by antigenic cells or antigen-bearing particles (usually erythrocytes, which may or may not be coated with antibody or antibody and complement). The rosette-forming cell may be an antibody-forming cell, a memory cell, a T-cell, a cell bearing surface cytophilic antibodies, or a monocyte possessing Fc receptors. Rosette formation can be used to identify specific populations of these cells. Immunocytoadherence,Formation, Rosette,Formations, Rosette,Immunocytoadherences,Rosette Formations
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte

Related Publications

T P Iakimova, and I N Lozinskaia, and T B Kozyreva, and N S Pashchenko
January 1985, Verhandlungen der Deutschen Gesellschaft fur Pathologie,
T P Iakimova, and I N Lozinskaia, and T B Kozyreva, and N S Pashchenko
September 1978, Cancer,
T P Iakimova, and I N Lozinskaia, and T B Kozyreva, and N S Pashchenko
January 1985, Nowotwory,
T P Iakimova, and I N Lozinskaia, and T B Kozyreva, and N S Pashchenko
January 2003, Cancer chemotherapy and biological response modifiers,
T P Iakimova, and I N Lozinskaia, and T B Kozyreva, and N S Pashchenko
October 1989, Cancer,
T P Iakimova, and I N Lozinskaia, and T B Kozyreva, and N S Pashchenko
February 1986, The American journal of medicine,
T P Iakimova, and I N Lozinskaia, and T B Kozyreva, and N S Pashchenko
March 1986, Presse medicale (Paris, France : 1983),
T P Iakimova, and I N Lozinskaia, and T B Kozyreva, and N S Pashchenko
February 1980, Harefuah,
T P Iakimova, and I N Lozinskaia, and T B Kozyreva, and N S Pashchenko
October 1981, Harefuah,
T P Iakimova, and I N Lozinskaia, and T B Kozyreva, and N S Pashchenko
January 1987, The Indian journal of medical research,
Copied contents to your clipboard!